Office of Acquisitions Management

Office of Acquisitions Management

Close: Jul 2, 2026

Offerors are encouraged to address the following areas, as applicable to the proposed effort, and may provide any additional technical or other information they deem pertinent. Platform technology: Provide a technical description of the platform technology, including details of the platform backbone/viral vector engineering and formulation. Nonclinical: Describe the nonclinical efficacy and immunogenicity data generated using the platform for BDBV and any other filoviruses; data supporting rapid onset of single-dose protection is a priority. See attached file.

Office of Acquisitions Management

Close: Jul 30, 2026

Seeks late-stage clinical development, regulatory approval for 2-PAM autoinjectors (as a drug/device combination product) to treat organophosphate (OP) poisoning, including nerve agents, in adult and pediatric populations, and procurement of 2-PAM autoinjectors for the SNS/CHEMPACK Program.

Office of Acquisitions Management

Close: Jun 21, 2026

Seeking: First-in-class small molecule or peptide-based antifungals that are currently in Phase 2 clinical trials or beyond (e.g., including FDA or EMA approved) with an intended treatment and prophylaxis indications or treatment only indication to address drug-resistant invasive fungal infections (e.g., Candida spp., including Candida auris, and/or Aspergillus species). Broad-spectrum candidates that are effective against yeast and molds and that are available as oral and IV are desirable. See attached file.